SCHEMBL3306489

SCHEMBL3306489

COc1ccc(/C=C/n2c(=O)sc3cc(OCCF)ccc32)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.43
LMNA P02545 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
PPARA Q07869 9/20 0.41
PPARG P37231 5/20 0.40
APP P05067 3/20 0.40
HTR6 P50406 2/20 0.38
FFAR1 O14842 1/20 0.37
PPARD Q03181 1/20 0.37
CYP3A4 P08684 1/20 0.37
ALDH1A1 P00352 2/20 0.36
MAPT P10636 2/20 0.36
TP53 P04637 1/20 0.36
HPGD P15428 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PKM P14618 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3306493 1.00 SMN1; SMN2 (0.43) SMN1; SMN2LMNANPC1RAB9APPARA
SCHEMBL13394309 0.83 NFE2L2 (0.47) SMN1; SMN2APPHTR6ALDH1A1MAPT
SCHEMBL14864458 0.82 HTR6 (0.50) SMN1; SMN2HTR6ALDH1A1MAPTTP53
SCHEMBL13394314 0.80 SMN1; SMN2 (0.45) SMN1; SMN2LMNANPC1RAB9AALDH1A1
SCHEMBL3305497 0.78 SMN1; SMN2 (0.54) SMN1; SMN2LMNANPC1RAB9ACYP3A4
SCHEMBL3305491 0.78 SMN1; SMN2 (0.54) SMN1; SMN2LMNANPC1RAB9ACYP3A4
SCHEMBL1850926 0.77 NFE2L2 (0.50) APPALDH1A1MAPT
SCHEMBL1850928 0.77 NFE2L2 (0.50) APPALDH1A1MAPT
SCHEMBL13394312 0.76 NFE2L2 (0.51) SMN1; SMN2APPHTR6ALDH1A1MAPT
SCHEMBL3307664 0.72 SMN1; SMN2 (0.47) SMN1; SMN2LMNANPC1RAB9ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420052-B2 Imaging agents useful for identifying AD pathology SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2013-04-16 US disclosed
US-8420052-B2 Imaging agents useful for identifying AD pathology SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2013-04-16 US disclosed
US-8420052-B2 Imaging agents useful for identifying AD pathology SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2013-04-16 US disclosed
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology SIEMENS MEDICAL SOLUTIONS USA, INC. 2010-04-22 US disclosed
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology SIEMENS MEDICAL SOLUTIONS USA, INC. 2010-04-22 US disclosed
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology SIEMENS MEDICAL SOLUTIONS USA, INC. 2010-04-22 US disclosed
WO-2010011964-A2 IMAGING AGENTS USEFUL FOR IDENTIFYING AD PATHOLOGY SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology APP, APBA1, PYGB SMN1; SMN2 69/4885LMNA 180/4885NPC1 719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.